Access to the PDF text

Free Article !

Archives of cardiovascular diseases
Volume 106, n° 4
pages 260-261 (avril 2013)
Doi : 10.1016/j.acvd.2013.03.043
Mitral valve replacement for functional mitral regurgitation in severe heart failure patients

A. Theron, P. Morer, N. Resseguier, F. Thuny, A. Riberi, R. Giorgi, F. Collart, G. Habib, J.-F. Avierinos
 La Timone, Marseille, France 

Background .– Type (undersizing annuloplasty–UA- vs. mitral valve replacement–MVR-) and outcome of surgical treatment of functional mitral regurgitation (FMR) are still debated.

Objectives .– Early and mid-term outcome of patients operated for symptomatic severe FMR; Comparison of respective results of UA and MVR.

Methods .– Inclusion criteria:

– severe FMR due to either ischemic or non-ischemic cardiac disease;

– heart failure symptoms despite optimal medical treatment;

– LVEF<40%.

Primary endpoints:

– in-hospital mortality;

– late CV mortality.

Secondary endpoints:

– evolution of LVEF after surgery;

– recurrence of MR.

Results .– Fifty-nine consecutive patients included between 1997 and 2011, mean age=65±10, ischemic disease in 41 (70%), heart failure symptoms in all, LVEF=36±6%, ERO=41±17mm2. Surgical procedures included 12UA and 47 MVR with only eight (13%) concomitant CABG. MVR and UA groups were comparable for age, ischemic etiology, LVEF, ERO and sPAP (all P >0.5). In-hospital mortality: 3.3% overall, 8.3% in UA group and 2.1% in MVR group (P =0.36). Eight-year survival free from CV death: 58±13% in the total population, 60±18% in the UA group and 72±10% in the MVR group (P =0.48). By multivariable analysis, older age (1.22 [1.05–1.42], P =0.008) and LV end-diastolic diameter (1.25 [1.05–1.49], P =0.01) independently predicted late mortality with borderline effect of pre-op LVEF (1.1[0.99–1.2], P =0.08) whereas type of surgery did not (1.7 [0,38–7.55], P =0.48). LVEF did not change between preop and late FU echo in the MVR group (36±6% vs. 36±10%, P =0.68) but tended to decrease in the UA group (37±5.8% vs. 31±12%, P =0.1). In the UA group, 50% of patients experienced recurrence of significant MR (mean postop ERO=19±4mm2) whereas no patients in the MVR group presented with postop MR.

Conclusions .– Despite severe clinical and echocardiographic presentation, surgical treatment of FMR can be performed with an acceptable operative risk and mid-term survival. MVR is a reasonable approach, which does not expose patients to MR recurrence, particularly frequent after UA.

© 2013  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline